Patents Examined by Christina Borgeest
  • Treatment of stroke using domain V of perlecan
    Patent number: 8466105
    Abstract: The present invention is drawn to methods of stimulating or enhancing angiogenesis in a patient comprising, administering to said patient a therapeutically effective amount of an endorepellin protein, wherein said endorepellin protein has an amino acid sequence of domain V of perlecan or fragments or derivatives, analogs thereof; and stimulating or enhancing generation of blood vessels. The present invention is drawn to compositions for enhancing angiogenesis.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: June 18, 2013
    Assignee: The Texas A&M University System
    Inventor: Gregory J. Bix
  • Oxytocin and melatonin compositions and associated methods for inducing labor
    Patent number: 8445436
    Abstract: The invention discloses a pharmaceutical composition containing oxytocin and melatonin in amounts therapeutically effective for inducing labor in a pregnant human patient. Preferably, the oxytocin content is reduced to mitigate unwanted side effects and the melatonin content synergistically enhances the oxytocin's labor-inducing effectiveness. Also disclosed is a pharmaceutical composition for treatment of a pregnant human patient experiencing pre-term labor characterized by early expression of melatonin receptors in myometrial cells, the composition containing one or more agents which interfere with melatonin binding to said receptors.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: May 21, 2013
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: James Olcese
  • Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
    Patent number: 8435948
    Abstract: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: May 7, 2013
    Assignees: Mount Sinai School of Medicine of New York University, University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Mone Zaidi, Harry C. Blair
  • Method of treating fibroproliferative disorders of the heart and lung
    Patent number: 8431129
    Abstract: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 30, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Follicle stimulating hormone superagonists
    Patent number: 8377879
    Abstract: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 19, 2013
    Assignee: Trophogen, Inc.
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
  • Transdermal delivery system for treating infertility
    Patent number: 8372806
    Abstract: The transdermal delivery system for treating infertility in a patient comprises an apparatus (10) for facilitating transdermal delivery of a drug (5a) through an area of the apparatus (10) comprises an ablator that is configured to generate a microporation in the area of the skin of the patient, and comprises a drug (5a), wherein the drug effects at least one of the biological regulation of at least one oocyte containing follicle, stimulation of follicle growth, induction of ovulation, promotion of gestational status, maintenance of conceptus, maintenance of pregnancy.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: February 12, 2013
    Assignee: Pantec Biosolutions AG
    Inventors: Christof Böhler, Thomas Bragagna, Reinhard Braun, Werner Braun, Herbert Zech
  • Activin-actriia antagonists for inhibiting germ cell maturation
    Patent number: 8367611
    Abstract: In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: February 5, 2013
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Matthew L. Sherman
  • Methods for enhancing fertility comprising administration of transfer factor
    Patent number: 8357663
    Abstract: Methods of promoting reproductive health in an animal by administering an effective amount of a composition containing at least one transfer factor are provided.
    Type: Grant
    Filed: November 30, 2008
    Date of Patent: January 22, 2013
    Assignee: The Ramaekers Family Trust
    Inventor: Joseph C. Ramaekers
  • HSA-free formulations of interferon-Beta
    Patent number: 8333958
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: December 18, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • sFRP and peptide motifs that interact with sFRP and methods of their use
    Patent number: 8334260
    Abstract: This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: December 18, 2012
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, St. Vincent's Institute of Medical Research
    Inventors: Jeffrey S. Rubin, Aykut Üren, Brian K. Kay, Bernard Weisblum, Matthew Todd Gillespie, Nicole Joy Horwood
  • Method of treating fibrproliferative disorders
    Patent number: 8298534
    Abstract: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: October 30, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for increasing FSH activity
    Patent number: 8293707
    Abstract: The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (?FSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (?FSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: October 23, 2012
    Assignee: Syntonix Pharmaceuticals, Inc.
    Inventor: Susan C. Low
  • Antibodies that specifically bind beta-like glycoprotein hormone polypeptides and heterodimers thereof
    Patent number: 8278422
    Abstract: Novel ?10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods for producing ?10 polypeptides and heterodimeric forms thereof, specifically ?2/?10. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with ?10 polypeptides and ?2/?10 heterodimers or their respective binding agents.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 2, 2012
    Inventor: Christopher J. R. Paszty
  • Implantable pump for protein delivery for obesity control by drug infusion into the brain
    Patent number: 8252744
    Abstract: Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: August 28, 2012
    Assignee: Codman & Shurtleff, Inc.
    Inventors: Vedrana Stojanovic-Susulic, Ramakrishna Venugopalan, Mark Cunningham
  • Methods for treating nervous system injury and disease
    Patent number: 8197804
    Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: June 12, 2012
    Assignee: Stemnion, Inc.
    Inventors: George L. Sing, Vivienne S. Marshall, Diana L. Clarke
  • Granulocyte colony stimulating factor for the treatment of an ovulation disorder caused by luteinized unruptured follicle
    Patent number: 8183205
    Abstract: A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 22, 2012
    Assignee: Satoru MAKINODA
    Inventor: Satoru Makinoda
  • Serpine2 as a biomarker for IgA nephropathy
    Patent number: 8178358
    Abstract: The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin ?4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: May 15, 2012
    Assignee: National Defense Medical Center
    Inventors: Ann Chen, Shuk-Man Ka
  • Activin-ActRIIa antagonists and uses for treating multiple myeloma
    Patent number: 8173601
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: May 8, 2012
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Prouroguanylin, and synthetic analogs or proteolytic cleavage products derived from it, as therapeutic and diagnostic agents for diseases involving salt and/or fluid homeostasis
    Patent number: 8173596
    Abstract: A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin in a sample.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: May 8, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Michael F. Goy, Nicholas G. Moss, Xun Qian
  • Anticalins
    Patent number: 8158753
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: April 17, 2012
    Assignee: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora